Marseille June 21st 2016, MI-mAbs, pre-industrial demonstrator to accelerate the development of new antibodies against cancer and inflammatory diseases, today announced the signing of a research contact with Innate Pharma and Sanofi. MI-mAbs will carry out studies to assess the effectiveness and safety of a new generation of bispecific antibodies resulting from the collaboration between the two manufacturers. Once this therapeutic window is validated, MI-mAbs will provide both partners with the list of the best antibody candidates for future clinical evaluations.
"This contract demonstrates the relevance of the MI-mAbs offer", said Professor Yvon Berland, President of Aix-Marseille University. "In addition to its mission as an innovation accelerator, MI-mAbs also enables our researchers and our Master students to access expertise and advanced technologies usually reserved for industrials. MI-mAbs is therefore at the core of the Marseille Immunopole cluster strategy, which aims to make our city not only a capital of immunotherapy research and development, but also a centre of education for fundamental and applied immunology".
"Because of their ability to force recognition of cancer cells by natural killer cells, bispecific antibodies raise the interest of industrials specializing in immuno-oncology, especially as they are beginning to demonstrate their clinical efficacy", said Professor François ROMAGNÉ, Scientific Director of MI-mAbs. "Still, their development also requires plenty of expertise and know-how, especially in pharmacology. By entrusting the selection and pharmacological validation of new bispecific antibodies to MI-mAbs, lnnate Pharma and Sanofi demonstrate their confidence in our team".